MRNS Forex News

Marinus Pharma Says Phase 3 Trial Of IV Ganaxolone In RSE Meets First Co-primary Endpoint

Pharmaceutical company Marinus Pharmaceuticals, Inc. (MRNS) announced Monday topline results from the Phase 3 double-blind, randomized, placebo-controlled RAISE trial evaluating the safety and efficacy of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE).

RTTNews | 142 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.073	GBPUSD	1.28835	AUDUSD	0.65788
USDJPY	154.106	USDCAD	1.39379	USDCHF	0.87527